Welcure Drugs Bags ₹5.17 Bn Global Sourcing Mandate, Eyes ₹258.5 Mn Service Income in FY26

Image Source : TradingView

Welcure Drugs and Pharmaceuticals Ltd. has executed a ₹5.17 billion global sourcing mandate, marking a major leap in its contract services portfolio. The mandate, which spans pharmaceutical raw materials and finished formulations, is expected to be fulfilled over FY 2025–26, positioning Welcure as a key procurement partner for international clients.

In tandem, the company has projected ₹258.5 million in service income for FY26, driven by its expanding role in supply chain facilitation, regulatory support, and quality assurance services. This dual development underscores Welcure’s strategic pivot toward high-margin, asset-light service models in the global pharma ecosystem.

Key Highlights:

Global sourcing mandate value: ₹5.17 billion
Service income guidance for FY26: ₹258.5 million
Scope: API sourcing, formulation procurement, regulatory and QA services
Client base: Global pharma companies across Europe, Asia, and Africa
Strategic impact: Strengthens Welcure’s positioning in pharma supply chain management
Financial outlook: Boosts topline visibility and margin profile for FY26

These developments reflect Welcure’s growing clout as a trusted sourcing and compliance partner in the global pharmaceutical value chain.

Source: BSE Corporate Filings – Welcure Drugs